How much does CARVYKTI (Ciltacabtagene Autoleucel) Cost& price without insurance in China?
CARVYKTI® is the commercial brand name of ciltacabtagene autoleucel, a BCMA-directed genetically modified autologous T-cell immunotherapy developed by Janssen Biotech. It involves engineering the patient’s own T cells to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), enabling them to recognize and eliminate BCMA-expressing multiple myeloma cells.
Main Indications
Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor, an immunomodulatory agent, and are refractory to lenalidomide.
Common Side Effects
Common mild adverse reactions: Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), fatigue, fever, nausea, and infections.
Laboratory abnormalities: Cytopenias (neutropenia, anemia, thrombocytopenia), hypogammaglobulinemia, and elevated liver enzymes.
Severe but uncommon risks: Severe or life-threatening CRS, severe ICANS, serious infections (including sepsis), prolonged cytopenias, and secondary malignancies.
Approval Status in China
CARVYKTI® (Ciltacabtagene Autoleucel) was officially approved for marketing in China in August 2024. It is currently a prescription CAR-T cell therapy for multiple myeloma.
Buy CARVYKTI (Ciltacabtagene Autoleucel) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
